

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Yes. Stakeholders noted that the Eczema Area and Severity Index (EASI) may underestimate the severity of atopic dermatitis in people with brown or black skin. They also noted people on low income may find it difficult to access treatment due to transportation costs. In addition, it was noted that the Dermatology Life Quality Index (DLQI) may not capture anxiety and depression in people with atopic dermatitis.

The committee concluded that, when using the EASI, healthcare professionals should take into account skin colour and how this could affect the EASI score. It also concluded that when using the DLQI, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's response to the DLQI.

In accordance with NICE's [social value judgement](#) principles, no priority is given based on individuals' income, social class, position in life or social roles in guidance developed for the NHS.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes Section 3.15

Approved by Associate Director (name): Emily Crowe...

Date: 23/05/2024